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Summary
Thyroid goiter is a common condition that is often
associated with iodine deficiency. Familial forms of
goiter in areas not known to feature iodine deficiency
are much less common. We have performed a genomic
search on a single large Canadian family with 18 cases
of nontoxic multinodular goiter in which 2 individuals
also had papillary lesions highly suggestive of papillary
carcinoma. A locus on chromosome 14q (MNG1
[multinodular goiter 1]) has been identified, with a
maximal two-point LOD score of 3.8 at D14S1030 and
a multipoint LOD score of 4.88 at the same marker,
defined by D14S1062 (upper boundary) and D14S267
(lower boundary). The gene encoding thyroid-
stimulating hormone receptor (TSHR), which is located
on chromosome 14q, is outside the linked region. To
determine the role of this gene in familial nonmedullary
thyroid cancer (NMTC), we studied 37 smaller
pedigrees each containing at least two cases of NMTC.
Analysis by both parametric and nonparametric
methods indicates that only a very small proportion of
familial NMTC (point estimate 0.001, support intervals
0–.6 under a dominant model) is attributable toMNG1.
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Introduction
Diffuse enlargement of the thyroid due to the develop-
ment of multiple nodules (i.e., thyroid goiter) is a com-
mon syndrome in many parts of the world. In some
geographic areas a high prevalence is attributable to io-
dine deficiency. However, even in areas without iodine
deficiency, multinodular goiter is common. For example,
in Framingham, MA, where iodine intake is ample,
1.1% of 5,234 persons examined were found to have
palpable multinodular thyroid goiters (Vander et al.
1954), and a smaller study performed in the north of
England yielded similar results (Tunbridge et al. 1977).
In fact, clinical examinationmay underestimate the prev-
alence of mild thyroid enlargement, since as many as a
third of all thyroid glands in one autopsy study con-
tained multiple nodules (Mortensen et al. 1955). The
female:male ratio is in excess of 5:1.
For a century it has been established that rare inherited
disorders of the thyroid gland can result in goiter (Pen-
dred 1896). A role for genetic factors in common multi-
nodular goiter has been supported by a study of Scottish
twins, in which the contribution of hereditary factors to
nontoxic, simple goiter in females was reported to be
∼40% (Greig et al. 1967), and by the existence of multi-
nodular-goiter families with vertical and/ormale-to-male
transmission (Murray et al. 1966; Couch et al. 1986;
Burgess et al. 1997) suggesting an autosomal dominant
susceptibility. Although the biochemical and genetic ba-
sis of many varieties of thyroid goiter have been eluci-
dated (Medeiros-Neto and Stanbury 1966; Rapoport et
al. 1972; De Groot et al. 1984; Ieiri et al. 1991), in most
sporadic and familial cases of multinodular-goiter, in-
vestigations fail to reveal any specific or consistent bi-
ochemical abnormality.
Susceptibility to medullary carcinoma of the thyroid
conferred by mutations in RET on chromosome 10 is
well recognized (Mulligan et al. 1993), but familial pre-
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disposition to nonmedullary thyroid cancer (NMTC) has
not been the subject of detailed investigation. Evidence
in support of susceptibility to NMTC derives from case
reports of families with multiple cases of NMTC and
from case-control and other population-based studies.
In these studies, the observed risk of NMTC in the first-
degree relatives of affected cases was elevated five- to
ninefold (Stoffer et al. 1986; Ron et al. 1987; Goldgar
et al. 1994). Although the population incidence of multi-
nodular goiter far exceeds that of thyroid carcinoma,
and although the two conditions have different age-at-
onset profiles (De Groot et al. 1984), there is also evi-
dence that genetic susceptibility to multinodular goiter
and to NMTC may be related. First, a history of benign
thyroid disease is a strong risk factor for the develop-
ment of thyroid cancer (Preston-Martin et al. 1987; Ron
et al. 1987). Second, families with multiple cases of
NMTC (reviewed in Houlston and Stratton 1995; Loh
1997) often have probands and relatives with benign
thyroid disease including multinodular goiter (Lote et al.
1980; Stoffer et al. 1986; Austoni 1988; Ozaki et al.
1988; Grossman et al. 1995). Finally, families segregat-
ing an autosomal dominant trait for multinodular goiter
often include cases of NMTC. Therefore, in this study
we have used a large Canadian pedigree, Montreal 236,
to search for a locus responsible for multinodular goiter
and then have assessed the contribution of this locus to
NMTC predisposition.
Subjects, Material, and Methods
Subjects
Subjects were recruited into the study from several
sources. Probands from Canadian families were
recruited via clinicians at McGill University. CRC020
was ascertained in the United States, whereas other
CRC families were referred by clinicians in the
United Kingdom. The IARC families were recruited
through the Consortium for the Genetics of Papil-
lary Thyroid Cancer (details of the families can be ob-
tained at http://www.geocities.com/ResearchTriangle/
4485/fnmtc.html).
The clinical features of MON236 have been reported
by Couch et al. (1986). In the Couch et al. study, 18
members of this pedigree were found to have adolescent-
onset euthyroid multinodular goiter. The pathology of
the thyroid glands that were available for examination
revealed typical features (multiple adenomata, epithelial
hyperplasia, calcification, and hemorrhage). Before
treatment, no consistent biochemical abnormalities were
present in any affected individual studied. We recon-
tacted the family, and a new branch of the family was
identified. By direct questioning of the 57 family mem-
bers who gave blood, we were able to recheck and up-
date the clinical status of these individuals. Three indi-
viduals (individuals 10, 15, and 22) (fig. 1) were of
uncertain status on review, on the basis of self-reported
absence of goiter (individual 10), disappearance of preg-
nancy-induced thyroid enlargement (individual 15), and
absence of characteristic pathological features of multi-
nodular goiter in the excised thyroid gland (individual
22). These three individuals were assigned to status “un-
certain” before the genomic search began.
MON152 is described in more detail by Druker et al.
(1997). In brief, the family contains five individuals in
two generations who have multinodular goiter. Two in-
dividuals, both of whom also had multinodular goiter,
developed follicular thyroid cancer. CRC020 was orig-
inally described by Stoffer et al. (1986) and contains five
individuals with papillary thyroid cancer and seven other
individuals with benign thyroid disorders. All pedigrees
are summarized in table 1. The study was approved by
the relevant institutional review boards.
Molecular Genetic Studies and Computational Analysis
Genome search.—Thirty-four individuals from
MON236 (in which there are 12 affected) were typed
with 214 markers, giving a resolution of ∼20 cM (Gya-
pay et al. 1994; Dib et al. 1996). The trait was likely
to be autosomally inherited, since male-to-male trans-
mission was seen in one pair of father and son (fig. 1),
and therefore no X-linked markers were analyzed. After
amplification by PCR, fluorescence-labeled products
were mixed and electrophoresed on an ABI 377 DNA
sequencer. Data were collected and analyzed by use of
Genescan collection software (version 1.1), Genescan
analysis software (version 2.02), and Genotyper (version
1.1). Regions of possible linkage were evaluated with
additional markers.
Haplotype analysis.—Haplotypes were determined for
chromosome 14q in the remaining 37 pedigrees by use
of 9–14 markers, from centromere to telomere (not all
markers were used for all pedigrees). The molecular
methods were as described for the genomic search. For
MON236 a dense chromosome 14q haplotype was con-
structed for all tested individuals, by use of 22 markers,
with the smallest number of recombination events being
assumed (fig. 1).
Statistical analysis.—For the genomic search, we as-
signed affection status to individuals, on the basis of
their status by age 50 years (or, for those !50 years, at
their current age). Affected individuals had physician-
reported nodular goiter with subsequent thyroid surgery
and/or thyroxine replacement. Unaffected individuals re-
ported no thyroid masses, surgery, or therapy by age 50
years (or, for those !50 years, at time of ascertainment).
For the other families, affection status was based on
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Figure 1 MON236 family. A reduced pedigree is shown with all typed individuals; bars denote all individuals with the at-risk haplotype,
together with those required for clarification of recombinations. Blackened symbols denote multinodular goiter; an asterisk (*) indicates those
with papillary tumors suggestive of papillary carcinoma; and a question mark (?) inside an unblackened symbol indicates that the individual
was assigned to status “uncertain” in the linkage analysis. The alleles for the markers D14S287 (cen) to D14S65 are shown. The segregating
haplotype is cen-4-3-2-2-4-4-4-3-1-3-2-1-2-5-3-4-3-7-1-tel, with the smallest region of sharing indicated in boldface. These four markers are
D14S1054, D14S265, D14S1030, and D14S1455. For individual 29, the only portion of the at-risk haplotype retained is 3-2-1-2. Of the three
individuals assigned status “uncertain,” individual 10 carriers the at-risk haplotype (3-2-1-2-5-3-4-3-?-1), whereas individual 15 does not;
individual 22 is untyped but could not receive the linked haplotype. Individual 35 carries the at-risk haplotype but is unaffected.
clinical and pathological reports and, for unaffected in-
dividuals, on personal report.
Two-point LOD scores were calculated for MON236
alone, by use of version 5.1 of the LINKAGE package
(Lathrop et al. 1984). The model used assumed an au-
tosomal dominant gene, frequency of .0001 with four
liability classes, penetrance .25 by age 20 years, pene-
trance .5 by age 30 years, and maximum penetrance .70
by age 50 years. Because the mode of inheritance of
NMTC is unknown, we analyzed our data from the 37
smaller pedigrees, using both parametric and nonpara-
metric approaches. In the parametric analysis of the
smaller families, both dominant and recessive models
were constrained to fit both the observed familial relative
risk of 8.0 (Goldgar et al. 1994) and a population prev-
alence of .002 (Parkin 1992). Under the dominant
model, we parameterized the gene frequency, penetrance,
and phenocopy rate to be .001, .18, and .0016, respec-
tively; under the recessive model, these parameters were
fixed at .05, .21, and .0015, respectively. For the mul-
tipoint analyses, the map order used was
D14S1062–0.08 cM–D14S1030–0.08 cM–D14S267;
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Table 1
Clinical Features of Families
Family







Individualsa Other Cancer(s) (No. of Cases)
MON236 Canadian/ Germany 3 18 G, 2? PTC Endometrial (1), bladder (1)
MON152 Canadian/ Ashkenazi Jewish 2 3 G, 2 FTC Colorectal (1), rhabdomyosarcoma
(1)
MON881 Canadian/ Ashkenazi Jewish 1 3 PTC )
MON883 Canadian/ Ashkenazi Jewish 1 2 PTC Colorectal (3), breast (1)
CRC019 United Kingdom (unspecified) 1 2 PTC Colorectal (1), endometrial (1),
stom-ach (1), brain (1), lung (1),
ovarian (1)
CRC020 United States/Ashkenazi Jewish 3 7 G, 5 PTC )
CRC127 Sri Lanka 1 1 PTC, 1 FTC )
CRC180 Anglo-Italian 1 2 PTC )
CRC238 United Kingdom (unspecified) 1 2 PTC, 1 N Colorectal (1), leukemia/lymphoma
(1)
CRC246 United Kingdom (unspecified) 2 2 PTC, 1 FTC Breast (1), colorectal (1), primary
site other/unknown (1)
CRC306 United Kingdom (unspecified) 2 2 PTC, 1 G Breast (2), colorectal (1), cervical (1)
CRC360 Maltese 1 2 PTC )
IARC01.01 France 2 2 PTC, 1 N Prostate (1), cutaneous melanoma (1)
IARC01.05 Italy 1 2 PTC, 1 N )
IARC01.06 France 3 2 PTC, 4 G, 1 N Cutaneous melanoma (1), brain (1),
primary site other/unknown (2)
IARC02.08 France 2 2 PTC, 1 G )
IARC02.10 France 1 3 PTC Colorectal (2), breast (2), primary
site other/unknown (2)
IARC01.12 France 2 2 PTC Breast (1), primary site other/un-
known (1)
IARC02.14 France 2 3 PTC, 1 G Leukemia/lymphoma(1), pancreatic
(2), colorectal (2)
IARC01.16 France 3 2 PTC, 1 G Primary site other/unknown (1)
IARC01.22 France 1 2 PTC, 1 N Renal cell (1)
IARC03.37 Spain/France 2 2 PTC )
IARC04.39 France 1 2 PTC )
1IARC02.41 France 2 3 PTC )
IARC07.45 Italy 2 2 PTC, 1 N )
IARC07.46 Italy 1 2 PTC )
IARC08.50 France 1 3 PTC )
IARC1.055 France 2 2 PTC, 1 G Prostate (1)
IARC1.056 France 2 2 PTC )
IARC11.61 Italy 1 2 PTC )
IARC11.62 Italy 1 2 PTC )
IARC1.063 Italy/France 2 2 PTC, 2 N Primary site other/unknown (1)
IARC02.65 France 1 2 PTC Colorectal (1)
IARC04.66 France 2 3 PTC, 1 G )
IARC14.74 France 2 4 PTC, 6 N )
IARC17.86 France 3 2 PTC, 1 N )
IARC02.88 France 2 2 PTC, 1 N Ovarian (1)
IARC02.89 France 1 2 PTC )
a G  nontoxic goiter only; N  single nodule; PTC  papillary thyroid cancer (with or without other thyroid disease); and FTC follicular
thyroid cancer. Not all affected individuals were analyzed.
published map distances between markers (in cM) were
converted to recombination fractions. Multipoint and
nonparametric analyses were performed by use of the
VITESSE and GENEHUNTER programs, respectively
(O’Connell and Weeks 1995; Kruglyak et al. 1996).
Results
Linkage in MON236
After the primary genome search, several markers on
chromosome 14q showed LOD scores 11.5, so addi-
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Table 2






P valuea .40 .40
a Nonparametric-linkage P values were generated by the nonpara-
metric method and test the significance of nonrandom sharing of alleles
among affected individuals.
Table 3
Point Estimates and 1  LOD Support Intervals for Estimated
Proportion of Linked Families
Model TSHR MNG1
Dominant .31 (0–.82) .001 (0–.6)
Recessive .02 (0–.45) .001 (0–.65)
tional markers in this region were analyzed (fig. 1). A
two-point LOD score of 3.8 at a recombination fraction
(v) of 0 was obtained with marker D14S1030. A mul-
tipoint LOD score of 4.88 was achieved with the use of
three chromosome 14q markers (D14S1062, D14S1030,
and D14S267), with a maximum at D14S1030. Because
of the uncertain status of individual 22, who had a single
follicular adenoma removed at age 23 years, we rean-
alyzed the data with this individual included as affected.
The multipoint LOD score fell to 4.34, with a maximum
3 cM distal to D14S1030. Construction of haplotypes
provided supportive evidence for linkage, and critical
recombinants placed MNG1 within a 1-cM interval
bounded by D14S1054 (centromeric) and D14S1455
(telomeric). Individual 35 carries the at-risk haplotype
and has not developed multinodular goiter at age 31
years (individual 10 also carries the at-risk haplotype,
but her affection status is uncertain; see above). There
are no unambiguous phenocopies in this family (see
above and fig. 1).
Several other regions showing positive LOD scores
were identified (D2S112, LOD score 1.03 at ;v  0
D4S1551, LOD score 1.39 at ; D7S502, LODv  .1
score 1.13 at ; D8S261, LOD score 1.14 atv  1.0
; and D15S128, LOD score 1.05 at ), butv  .15 v  .15
all were excluded as candidate loci, on the basis of both
examination of additional markers in the vicinity and
the nonsharing of haplotypes by affected individuals. As
discussed above, because of the uncertain status of in-
dividual 22, we recalculated all the two-point LOD
scores, assuming her to be affected. The LOD scores did
not change substantially for any locus. A new locus,
D12S366, did generate a LOD score of 0.8, and the
haplotype is shared by many affected family members.
However, the two pairs of affected sibs—pair 12 and 13
and pair 33 and 34—do not share haplotypes at this
locus, making it unlikely that this locus is segregating
with the disease.
TSHRwas identified as a strong candidate gene before
the genome search began, but no mutations were seen
in TSHR in four affected individuals from two families,
MON236 and MON152 (data not shown). Moreover,
recombinations in affected individuals 8, 13, 28, 29, and
30 from MON236 appear to have eliminated this gene
genetically.
Linkage Analyses in the Smaller Thyroid Cancer
Families
In family MON236, we identified a chromosome 14
region, bounded by D14S1062 and D14S267, that seg-
regated with multinodular goiter. Another family with
multiple cases of multinodular goiter, MON152, also
showed evidence of linkage to this region. In this family
we genotyped seven individuals (four affected) and ob-
tained a maximal two-point LOD score of 0.57 at v 
from D14S1030. This family contains two individ-.03
uals who, in addition to multinodular goiter, also had
follicular thyroid cancer. The segregating haplotype dif-
fers from that seen in MON236. For MON152,
the haplotype for markers D14S1054, D14S265,
D14S1030, and D14S1455 is 3-5-6-2, whereas it is 3-
2-1-2 for MON236.
Because both MON236 and MON152 contain cases
of NMTC in addition to goiter, and because goiter is a
known risk factor for NMTC, we evaluated the contri-
bution of MNG1 to familial NMTC. We studied 37
NMTC families collected in Europe and North America
during the past few years. At least nine chromosome
14q markers were studied in all 37 families, and para-
metric and nonparametric linkage analyses were per-
formed. In table 2, we present the LOD scores and the
P values for two locations of interest on chromosome
14: TSHR andMNG1.Although no evidence for linkage
at either region was found, we recognize that there could
still be some fraction of NMTC families whose disease
is attributable to either of the chromosome 14 loci. To
examine this statistically, an analysis was performed un-
der the assumption that a subset of families were linked
to the candidate region while the rest were unlinked.
Although, for MNG1, the point estimate of the linked
fraction in these cases were close to zero (.001), we could
not, on the basis of our linkage analyses, formally ex-
clude the possibility that a significant fraction of cases
were due to these regions (table 3). In addition, we per-
formed a separate analysis using not only NMTC but
also goiter or nodule as affection status. No evidence of
linkage was detected (results not shown). In conclusion,
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both parametric and nonparametric linkage analyses in-
dicate that it is unlikely that either MNG1 or TSHR
contributes significantly to susceptibility to NMTC.
Discussion
Multinodular-Goiter Kindreds
In this study, we have presented evidence in favor of
linkage of multinodular goiter to a locus on chromosome
14q in a single large family (MON236).Weaker evidence
in favor of linkage was obtained in a second family with
multinodular goiter. Apart from MON236, four sub-
stantial pedigrees with euthyroid multinodular goiter
have been reported. A large African American kindred
with congenital goiter and follicular carcinoma was re-
ported in 1981 by Cooper et al. (1981). In this kindred,
a mother and 7 of her 14 children had goiter, and 2 of
those children with goiter also developed metastatic fol-
licular thyroid carcinoma. Biochemical studies showed
very rapid rates of iodine turnover, and the authors of
that study suggested that an abnormality of thyroid-
stimulating hormone (TSH) was likely. The mode of in-
heritance was uncertain. A five-generation Scottish kin-
dred with adolescent-onset goiter associated with
marked age-dependent intrathyroid calcification was re-
ported 130 years ago (Murray et al. 1966). Although
there were some abnormalities of thyroid function, these
did not fit any known familial disorder. The inheritance
pattern was dominant, but a sex-linked trait cannot be
excluded from the pedigree published in that article. Re-
cently, two apparently unrelated pedigrees from Tas-
mania with dominantly inherited multinodular goiter
have been reported. One pedigree is very large, contain-
ing 17 members (13 females and 4 males) with clinically
or screen-detected multinodular goiter, 6 of whom have
developed pathologically confirmed papillary thyroid
cancer. One individual without goiter had a solitary nod-
ule, within which papillary thyroid cancer was identified
after excision. On the basis of historical report, five gen-
erations of this family have developed thyroid neoplasia.
The other pedigree is smaller, but, interestingly, contains
MZ twin males, each of whom has one daughter. All
four individuals have developed papillary thyroid cancer
with or without multinodular goiter. The daughter of
another brother also has multinodular goiter (Burgess
et al. 1997).
Candidate Multinodular-Goiter Genes
TSHR is located on chromosome 14q and is a plau-
sible mechanistic candidate for susceptibility to multi-
nodular goiter. Moreover, germ-line mutations in TSHR
have been reported in two families from France that have
numerous cases of goiterous, nonautoimmune autoso-
mal dominant hyperthyroidism (Duprez et al. 1994), and
somatic mutations in TSHR have been detected in hy-
perfunctioning thyroid adenomas (Parma et al. 1993).
TSHR appears to be excluded, however, as a candidate
gene for multinodular goiter in the present study, by
recombination in five individuals from MON236 and
by the absence of mutations in two affected individuals
from both MON236 and MON152 (data not shown).
Other notable candidates elsewhere in the genome that
were excluded by linkage analysis include the thyroglob-
ulin gene on chromosome 8q (which is mutated in
nonendemic goiter; Corral et al. 1993) and RET and
PTEN, both located on chromosome 10q (mutations of
PTEN are responsible for Cowden disease; Liaw et al.
1997) (data not shown). Taken together, the data suggest
that a novel locus (designated “MNG1”) responsible for
multinodular goiter is present on chromosome 14q. Fur-
ther studies will now evaluate whether other families
segregating an autosomal dominant trait for multinodu-
lar goiter are linked to this locus. Subsequently posi-
tional cloning of MNG1 will allow estimation of the
contribution of abnormalities in this gene to multinodu-
lar goiter in the general population.
MNG1 and Familial NMTC
Because NMTC is present in several families ascer-
tained with multinodular goiter, and vice versa, we have
evaluated the contribution ofMNG1 to NMTC suscep-
tibility. Although we cannot completely exclude a con-
tribution by MNG1, it is clear that this gene (and also
TSHR) does not account for most susceptibility to
NMTC. Other candidates for susceptibility to NMTC
include RET and PTEN, and assessment of these loci is
underway. However, localization of NMTC genes by
genomewide search may be problematic, because the
number of families available for study is limited, kin-
dreds with multiple cases of NMTC without goiter are
exceptionally uncommon, and the degree of genetic het-
erogeneity is unknown. Nevertheless, the set of NMTC
families documented here is the largest reported and pro-
vides the basis for further studies to identify NMTC
genes.
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